We have recently shown that thyroid hormone in physiological concentrations stimulates sarcolemmaenriched rabbit-myocardial-membrane Ca2+-ATPase in vitro. In this study, milrinone [2-methyl-5-cyano-(3,4'-bipyridin Ca2+-ATPase. Amrinone [5-amino-(3,4'-bipyridin)-6(1H)-one], the parent bipyridine of milrinone, had no effect on myocardial Ca2+-ATPase activity. X-ray crystallographic analysis of milrinone and amrinone revealed structural homologies between the phenolic ring of thyroxine and the substituted ring of milrinone, whereas amrinone did not share these homologies. The mechanism(s) of the inotropic actions of thyroxine and of milrinone is not clearly understood, but these observations implicate Ca2+-ATPase, a calcium pump-associated enzyme, as one mediator ofthe effects on the heart ofthese two compounds.Milrinone [2-methyl-5-cyano-(3,4'-bipyridin)-6(1H)-one] is a nonglycosidic positive-inotropic bipyridine (1, 2) whose biochemical mechanism of action on the heart has not been -established. The action of the bipyridines could involve either phosphodiesterase inhibition and cyclic AMP accumulation (3)(4)(5) or increasing the rate of calcium sequestration (6). The drug has a bipyridine structure whose substituted ring has features that might mimic those of the thyroid hormones, thyroxine (T4) or triiodothyronine (T3); this caused us to examine milrinone for stimulatory action on rabbit myocardial membrane Ca2+-ATPase activity. We have previously reported that physiological concentrations of thyroxine (0.10 nM) stimulate this myocardial membrane calcium pump-associated enzyme in vitro via a calmodulin-dependent process (7). This Ca2+-ATPase is thought to be responsible for calcium ejection by myocardial cells during rest.